Lung cancer screening with low dose CT requires careful consideration

Research output: Contribution to journalReviewResearchpeer-review

Zaigham Saghir, Haseem Ashraf, Karen Skjøldstrup Bach, John Brodersen, Paul Frost Clementsen, Martin Døssing, Hanne Hansen, Klaus Fuglsang Kofoed, Klaus Richter Larsen, Jann Mortensen, Jakob Fraes Rasmussen, Laura Hohwü Thomsen, Mathilde Marie Winkler Wille, Niels Seersholm, Birgit Guldhammer Skov, Hanne Thorsen, Philip Tønnesen, Jesper Holst Pedersen

Results from the American National Lung Screening Trial (NLST) show a significant reduction in lung cancer and all-cause mortality in a high risk population screened with annual low-dose CT. Handling of pulmonary nodules, false positive tests, overdiagnosis, psychosocial consequences and cost-efficiency etc. are all aspects that require careful consideration. This paper gives an overview of the current knowledge on these issues. Before a recommendation can be made, we need an overall evaluation of both the benefits and harms in CT screening for lung cancer.

Original languageEnglish
JournalUgeskrift for Laeger
Issue number42
Publication statusPublished - 13 Oct 2014

ID: 221821709